Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could your own immune cells keep liver cancer from coming back?

NCT ID NCT07709299

Disease control Sponsor: Royan Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This trial investigates whether giving liver cancer patients infusions of their own immune cells, called cytokine-induced killer (CIK) cells, after surgery is safe and feasible. The cells are collected from the patient's blood, grown in a lab, and then returned through six intravenous infusions over two months. The study includes up to 6 participants with early-stage liver cancer who have had their tumor removed, and follows them for six months to monitor side effects and early signs of recurrence.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a patient's own immune cells (cytokine-induced killer cells) grown in a lab and given back as infusions
What this could lead to
If safe and feasible, this approach could offer a new way to reduce the risk of liver cancer returning after surgery.
What could go wrong
This is a very early, small trial with only 6 participants, so results may not apply broadly. The treatment could cause side effects or fail to prevent cancer recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 6 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 80 years * Documented HCC at BCLC stage 0-A, having undergone surgical tumor resection * Single tumor or ≤3 nodules, each ≤3 cm * Child-Pugh score A-B * ECOG performance status 0-1 * Confirmed cancer-free status one month after surgery * Written informed consent * Leukocyte count \> 3 × 10⁹/L * Absolute neutrophil count (ANC) ≥ 1,000/µL * Hemoglobin ≥ 8.5 g/dL * Platelet count \> 50 × 10⁹/L * BUN and serum creatinine ≤ 1.5 × upper limit of normal No extrahepatic abdominal disease spread, confirmed by abdominal CT/MRI Exclusion Criteria: * Active infection or uncontrolled viremia (particularly HBV, HCV, or HIV) * Any cell therapy or immunotherapy in the past 6 months, or current participation in another clinical study * Another malignancy (prior or concurrent) differing from HCC in primary site or histology * Clinically significant cardiovascular disease (e.g., heart failure, serious arrhythmia, symptomatic coronary artery disease) * History of organ transplantation * Primary or secondary immunodeficiency, or active autoimmune disease * Severe allergic disorder or history of anaphylaxis * Pregnancy or breastfeeding at study entry * Women of childbearing potential intending to become pregnant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma (HCC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Liver Transplant and Surgery Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences

    Tehran, Tehran Province, Iran

More trials for these conditions

Other studies related to the condition(s) this trial covers.